RT Journal Article
SR Electronic
T1 Artificial intelligence-based histopathology image analysis identifies a novel subset of endometrial cancers with distinct genomic features and unfavourable outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.23.23290415
DO 10.1101/2023.05.23.23290415
A1 Darbandsari, Amirali
A1 Farahani, Hossein
A1 Wiens, Matthew
A1 Cochrane, Dawn
A1 Asadi, Maryam
A1 Mirabadi, Ali Khajegili
A1 Jamieson, Amy
A1 Farnell, David
A1 Ahmadvand, Pouya
A1 Douglas, Maxwell
A1 Leung, Samuel
A1 Abolmaesumi, Purang
A1 Jones, Steven JM
A1 Talhouk, Aline
A1 Kommoss, Stefan
A1 Gilks, C Blake
A1 Huntsman, David G.
A1 Singh, Naveena
A1 McAlpine, Jessica N.
A1 Bashashati, Ali
YR 2023
UL http://medrxiv.org/content/early/2023/07/12/2023.05.23.23290415.abstract
AB Endometrial cancer (EC) has four molecular subtypes with strong prognostic value and therapeutic implications. The most common subtype (NSMP; No Specific Molecular Profile) is assigned after exclusion of the defining features of the other three molecular subtypes and includes patients with heterogeneous clinical outcomes. In this study, we employed artificial intelligence (AI)-powered histopathology image analysis to differentiate between p53abn and NSMP EC subtypes and consequently identified a novel sub-group of NSMP EC patients that had markedly inferior progression-free and disease-specific survival (termed ‘p53abn-like NSMP’), in a discovery cohort of 368 patients and an independent validation cohort of 290 patients from another center. Shallow whole genome sequencing revealed a higher burden of copy number abnormalities in the ‘p53abn-like NSMP’ group compared to NSMP, suggesting that this new group is biologically distinct compared to other NSMP ECs. Our work demonstrates the power of AI to detect prognostically different and otherwise unrecognizable subsets of EC where conventional and standard molecular or pathologic criteria fall short, refining image-based tumor classification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTerry Fox Research institute, Canadian Institute for Health Research, Natural Sciences and Engineering Research Council of Canada, Michael Smith Health Research, UBC & VGH FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of British Columbia - BC Cancer Research Ethics Board (UBC BC Cancer REB)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript